Hidradenitis suppurativa, which is linked with microbial dysbiosis and immune dysregulation, is defined by recurrent nodules, tunnels and scarring, primarily in skin folds; the review found a multitude of antimicrobial peptides expressed in this skin disease.
A recent literature review examined the role of skin-produced antimicrobial peptides (AMPs) in hidradenitis suppurativa (HS), a chronic, inflammatory skin disease in hair follicles.
HS, which is linked with microbial dysbiosis and immune dysregulation, defined by recurrent nodules, tunnels and scarring, primarily in skin folds. Previous work has shown dysregulated levels of AMPs in HS. AMPs are key defense players in innate immunity and help fight microbial invasion, particularly against Gram-positive and Gram-negative bacteria, as well as some fungal and viral agents. They are also strong immunomodulators and have been implicated in several chronic inflammatory conditions in the epithelium of the intestines, airways, and skin.
Researchers screened PubMed, Embase, and the Cochrane Library, ultimately choosing 18 retrospective and prospective studies published between 2009 and 2020.
Of the 18 studies:
In addition, 8 studies analyzed both mRNA and protein levels of AMPs; 3 studies only analyzed mRNA levels; 7 studies analyzed protein levels.
For mRNA analysis, most studies used quantitative real-time polymerase chain reactions (qPCR); for protein analysis, most studies used immunohistochemistry (IHC).
Results showed that members of the human β-defensin (hBD) and S100 protein families were the most commonly investigated AMPs. S100 proteins are expressed in the epidermis and regulate of cell proliferation and differentiation.
The studies found a consistent overexpression of hBD-2, S100A7, S100A8 and S100A9 at both the mRNA and protein levels, and a decreased expression of hBD-1. The mechanisms behind the lower levels of hBD-1 in the development of HS remain unclear. Evidence was mixed on the involvement of hBD-3 in HS, with 4 studies reported upregulation of hBD-3 mRNA and protein and 3 studies finding no upregulation of hBD-3 mRNA or protein
Overall, the studies indicate a dysregulation of AMPs in both lesional and nonlesional HS skin.
“Future studies investigating epigenomic, genomic and protein expression are warranted to achieve a more comprehensive view of their potential significance in the pathogenesis of HS,” concluded the authors.
Reference
Yao Y, Frew JW, Thomsen SF, Ring HC. Antimicrobial peptides in hidradenitis suppurativa: A systematic review. Br J Dermatol. Published online September 9, 2021. doi: 10.1111/bjd.207
Addressing Financial Aid and Patient Independence as Part of Atopic Dermatitis Care
March 13th 2025Discussions centered on mitigating the financial burden of pediatric atopic dermatitis through financial aid programs and enhancing support for young patients to independently manage their condition were emphasized at this year’s 2025 American Academy of Dermatology meeting.
Read More
Redesigning Inpatient Dermatology to Address Costs, Improve Access
February 20th 2025The clinical and financial implications of inpatient dermatology were examined, highlighting the need for systemic changes to improve care, reduce costs, and address health equity for patients with skin diseases.
Read More
AI-Enabled Wearable Sensor Reduces Scratching in Atopic Dermatitis
February 11th 2025Patients with mild atopic dermatitis who reported nighttime scratching experienced relief when they used an artificial intelligence (AI)-powered wearable sensor that delivered haptic feedback on sleep behaviors.
Read More
Dermocosmetics as Adjunctive Therapy Reduces Sensitivity and Improves Quality of Life in Acne
January 22nd 2025Dermocosmetics alongside traditional acne treatments improved skin tolerance and reduced acne severity in patients, particularly those using retinoids, leading to enhanced quality of life.
Read More